Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging scientific and clinical trial facilities at the University of Southampton and Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development. Core to Synairgen’s business strategy is the realisation of value via licensing transactions – validated in June 2014 by the SNG001 agreement formed with AstraZeneca. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see
Southampton, GB
Size (employees)
12 (est)-7%
Synairgen is headquartered in Southampton, GB

Synairgen Office Locations

Synairgen has office in Southampton
Southampton, GB

Synairgen Metrics

Synairgen Summary

Market capitalization

£27.9 m

Closing share price

Synairgen's current market capitalization is £27.9 m.

Synairgen Financials

Synairgen's revenue is £4.3 m in FY, 2014 which is a 17060% increase from the previous period.
FY, 2014FY, 2015


£4.3 m£25 k

Revenue growth, %


Synairgen Market Value History

We estimate that Synairgen's current employees are approximately 8% female and 92% male.

Synairgen Online Presence

Synairgen Company Life

You may also be interested in